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Chronic lymphocytic leukemia (CLL) is an adult B cell
malignancy. Genome-wide association studies show
that variation at 15q15.1 influences CLL risk. We
deciphered the causal variant at 15q15.1 and the
mechanism by which it influences tumorigenesis.
We imputed all possible genotypes across the locus
and thenmapped highly associated SNPs to areas of
chromatin accessibility, evolutionary conservation,
and transcription factor binding. SNP rs539846
C>A, the most highly associated variant (p = 1.42 3
1013, odds ratio = 1.35), localizes to a super-
enhancer defined by extensive histone H3 lysine 27
acetylation in intron 3 of B cell lymphoma 2 (BCL2)-
modifying factor (BMF). The rs539846-A risk allele al-
ters a conserved RELA-binding motif, disrupts RELA
binding, and is associated with decreased BMF
expression in CLL. These findings are consistent
with rs539846 influencing CLL susceptibility through
differential RELA binding, with direct modulation of
BMF expression impacting on anti-apoptotic BCL2,
a hallmark of oncogenic dependency in CLL.INTRODUCTION
Although genome-wide association studies (GWASs) frequently
have identified statistically significant associations within non-
coding regions of the genome, the underlying causal variant
has been elucidated in only a few instances. GWASs of chronic
lymphocytic leukemia (CLL) have identified 31 risk loci, withCell Re
This is an open access article undthe signal annotating B cell lymphoma 2 (BCL2)-modifying factor
(BMF) at 15q15.1 being highly robust (Berndt et al., 2013, 2016;
Crowther-Swanepoel et al., 2010; Di Bernardo et al., 2008;
Slager et al., 2011, 2012; Speedy et al., 2014).
Elevated expression of the anti-apoptotic protein BCL2 is
a hallmark of CLL, driving the accumulation of mature leukemic
lymphocytes (Hanada et al., 1993). BMF, a BH3-only pro-
apoptotic member of the BCL2 protein family, neutralizes the
anti-apoptotic activity of BCL2 through direct interaction (Putha-
lakath et al., 2001). Here we sought to identify the causal poly-
morphism(s) driving the 15q15.1 association with CLL suscepti-
bility as a basis for understanding BCL2 addiction mechanisms
in CLL.RESULTS
Fine-Mapping of the 15q15.1 CLL Risk Locus
A previous GWAS reported an association between rs8024033
at 15q15.1 and CLL risk (Berndt et al., 2013). To refine the
association signal, we performed fine-mapping of the 15q15.1
CLL risk locus by imputation of our European GWAS to 1000
Genomes Project (Abecasis et al., 2012) and UK10K (UK10K
Consortium et al., 2015) reference panels. By this approach,
we identified four risk SNPs with minor allele frequency >0.01
and association p < 5.0 3 107 (Figure 1A; Table S1). The
lead SNP, rs539846 (odds ratio = 1.35, p = 1.42 3 1013),
mapped to the third intron of BMF and was in high linkage
disequilibrium (LD, r2 = 0.91) with the published SNP,
rs8024033. We verified the fidelity of imputed rs539846 geno-
types by Sanger sequencing in a subset of 176 CLL cases,
demonstrating >95% concordance.
To rule out the existence of multiple statistical signals at
the BMF locus, we repeated association testing conditional onports 16, 2061–2067, August 23, 2016 ª 2016 The Author(s). 2061
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Genetic Mapping and Epigenetic
Landscape at the 15q15.1 Locus
(A) SNAP plot of the 15q15.1 chronic lymphocytic
leukemia susceptibility locus. Genotyped (tri-
angles) and imputed (dots) SNPs are shown based
on their megabase chromosomal position on the
x axis and -log10 p value on the y axis. Color in-
tensity of each symbol reflects the extent of LD
with rs539846 (white r2 = 0 to dark red r2 = to 1).
Recombination rates, estimated using HapMap
samples of European ancestry, are shown by a
light blue line. Physical positions are based on
NCBI build 37 of the human genome. Also shown
are relative gene positions and chromatin state
segmentation (ChromHMM) for GM12878 derived
from ENCODE project data.
(B) ChIP-seq data for H3K4Me1, H3K4Me3, and
H3K27Ac histone modifications and DNaseI hy-
persensitivity (HS) are illustrated for GM12878
from ENCODE (brown) and for CLL cells from the
Blueprint Project (blue). ChIP-seq data for RELA
in GM12878 also is shown. Data are shown rela-
tive to the genomic arrangement of BMF and
were plotted in the University of California, Santa
Cruz Genome Browser. Also illustrated are
the position-weighted matrix for RELA and the
motif sequence (underlined) altered by rs539846
(red box).rs539846 genotypes, observing no significant variants (most sig-
nificant variant: rs181168015, p = 1.52 3 104; Figure S1). We
also found no rare non-synonymous variants inBMF in the germ-
line exomes of 141 CLL cases (enriched for genetic susceptibility
by virtue of family history; Supplemental Experimental Proce-
dures). Collectively these results are consistent with a single un-
derlying variant at the 15q15.1 locus.
Definition of rs539846 as a Plausible CLL Risk SNP
To further prioritize candidate CLL risk variants, we examined
the regulatory potential of SNPs in LD (r2 > 0.2) with rs539846,
based on epigenetic data from lymphoblastoid cell lines (LCLs
[ENCODE Project Consortium, 2012]) and primary CLL cells.
These data showed that rs539846 resides within an active2062 Cell Reports 16, 2061–2067, August 23, 2016enhancer region inferred byDNaseI sensi-
tivity and H3K4me1 and H3K27ac histone
modifications inbothcell types (Figure1B;
Table S1). Moreover, analysis of histone
H3K27ac data from lymphoid cells of
both B cell and T cell lineages defined a
B cell-specific 15q15.1 super-enhancer
that spans 80 kb, encompassing the
CLL risk locus (Hnisz et al., 2013), while
high-throughput chromosome conforma-
tion capture (Hi-C) data from LCLs (Rao
et al., 2014) show that this putative
super-enhancer element overlaps a chro-
matin contact domain (Figure 2A).
Since causal SNPs that drive GWAS
associations may function by alteringtranscription factor binding, we examined whether 15q15.1
candidate risk SNPs disrupt predicted JASPAR motifs. This
revealed that rs539846 alters a highly conserved base within a
putative RELA-binding motif (GGGACTTT[C/A]C, phastCons
score = 1.00, Genomic Evolutionary Rate Profiling [GERP]
score = 4.81) (Figure 1B). Encyclopedia of DNA Elements
(ENCODE) transcription factor chromatin immunoprecipitation
sequencing (ChIP-seq) in LCLs confirmed the presence of
RELA binding across this site (Figure 1B) in cells homozygous
for the rs539846-C allele (non-risk allele, preserving the RELA
motif). Within the 15q15.1 chromatin contact domain, chromo-
some conformation capture–on-chip with sequencing (4C-seq)
in the MEC1 CLL cell line showed a high frequency of three-
dimensional contacts between the viewpoint (adjacent to
Figure 2. Contact Profile of the BMF 4C
Viewpoint in Combination with ChIP-Seq
Data
(A) Heatmap representing chromatin interactions
in GM12878 cells at 40.32–40.52 Mb on chromo-
some 15. Chromatin contact domains called by
the Arrowhead algorithm aremarked by white lines
(Rao et al., 2014). The contact domain and CD19+
B cell super-enhancer (Hnisz et al., 2013) encom-
passing rs539846 are labeled in pink and yellow,
respectively.
(B) 4C-seq analyses in MEC1 CLL cells indicate
the formation of a loop domain between rs539846
and cis-regulatory elements. The 4C viewpoint
(green box) lies adjacent to rs539846 (dotted line).
A 10-kb masked region (gray box) is also marked.
ENCODE ChIP-seq data from GM12878 cells
show the correspondence between loop formation
and CTCF and RELA transcription factor occu-
pancy. Canonical transcripts and chromosome 15
position also are shown.rs539846) and the distal end of the predicted super-enhancer,
with both points overlapping regions of RELA and CTCF binding
(Figure 2B).
No other candidate CLL risk variant at the 15q15.1 locus
showed the unique combination of evolutionary conservation,
active enhancer localization, and disruption of a transcription
factor-binding motif, thus re-affirming that rs539846 is the single
best causal SNP candidate.
rs539846 Alters RELA-Mediated Enhancer Activity
We next performed luciferase reporter assays to determine the
effect of rs539846 on enhancer activity. MEC1 cells transfected
with constructs containing the risk A allele demonstrated a sig-
nificant reduction in normalized luminescence compared to the
C allele (p = 0.015, Figures 3A and 3B), indicating that the intact
RELA motif is required for enhancer activity. We assayed pro-
tein-DNA interactions for rs539846-C and -A alleles using elec-
trophoretic mobility shift assays (EMSAs). The C allele formed
stronger protein-DNA complexes compared with the A allele
(Figure 3C), and in an EMSA super-shift assay RELA was prefer-
entially recruited to the C allele (Figure 3C).
rs539846 Alters RELA-Mediated Regulation of BMF
To determine whether BMF is a target of RELA-mediated regula-
tion, we first queried the International Cancer Genome Con-
sortium (ICGC) dataset, revealing a correlation between RELA
and BMF expression in CLL (Table S2; p = 0.004). To establish
a direct relationship between RELA and BMF expression, we
performed small interfering RNA (siRNA) experiments in MEC1Cell Repcells, where knockdown of RELA was
accompanied by a significant reduction
in BMF mRNA (Figure 4A, p = 0.02; Fig-
ure S2). We also investigated whether
the rs539846 genotype was associated
with BMF transcript levels in 426 primary
CLL cases. We observed a significantdose relationship between the rs539846-A risk allele and
reduced BMF mRNA (p = 0.0003; Figure 4B). No association
was seen between the rs539846 genotype and levels of other
genes within 1 Mb of the SNP (false discovery rate < 0.05, Table
S2). To investigate whether the rs539846 genotype might influ-
ence splicing of BMF, we examined RNA sequencing (RNA-
seq) data from 30 CLL cases, finding no evidence of aberrant
splicing. We also found no differences in the splicing levels of
known BMF exons between the rs539846 risk allele and non-
risk allele homozygotes (Figure S3).
Impact of rs539846 on Prognosis and Survival in CLL
Patients
CLL can be classified on the basis of several prognostic factors,
including immunoglobulin heavy-chain variable (IGHV) mutation
status; expression levels of CD38, ZAP70, and CLLU1; as well
as somatic genomic abnormalities (trisomy 12, 13q14 deletion,
6q21 deletion, 11q23 deletion, 17p13 deletion, NOTCH1 muta-
tion, and SF3B1 mutation). We found no association between
the rs539846 genotype and these features in a subset of UK-
GWAS and ICGC study cases (Table S3). There was also no
association between rs539846 and overall patient outcome
(Table S4), and we noted that BMF transcript levels were not
associated with patient survival (Table S4).
DISCUSSION
Collectively, our data demonstrate that the underlying molecular
mechanism for the 15q15.1 CLL risk locus is mediated throughorts 16, 2061–2067, August 23, 2016 2063
Figure 3. rs539846 Affects RELA-Bound Enhancer Activity
(A) Allele-specific constructs containing a 591-bp putative regulatory sequence flanking rs539846 were cloned into the pGL3-promoter luciferase reporter vector.
(B) The ratio of luminescence from the experimental pGL3-rs539846 constructs to the Renilla internal control, pRL-SV40, was normalized to the empty pGL3-
SV40 vector. Data shown are mean ± SE from three independent experiments performed in triplicate. Difference in expression was assessed by the Student’s
t test. The rs539846-A risk allele had significantly decreased enhancer activity over the protective allele.
(C) EMSA showing differential binding of MEC1 nuclear protein to the rs539846-C allele (protective) and the rs539846-A allele (risk). Binding of double-stranded A
allele and C allele probes to MEC1 nuclear extract shows a marked reduction of DNA-protein binding associated with the A allele.rs539846, which resides within a transcriptional enhancer and
disrupts a conserved RELA transcription factor-binding site.
Our data are compatible with the rs539846-A allele conferring
increased CLL risk through reduced RELA-mediated expression
of the pro-apoptotic BCL2 family gene, BMF. Furthermore,
epigenetic and chromosome conformation capture data are
consistent with rs539846 localizing within a chromatin contact
domain, overlapping a B cell super-enhancer (Hnisz et al.,
2013). This interval, anchored by divergent CTCF-binding sites,
forms a loop domain (Rao et al., 2014), which is expected to bring
two regions of RELA binding, separated by a linear distance
of around 65 kb, into physical contact close to the promoter
of BMF.
RELA (also known as p65) is a sub-unit of the necrosis factor
kappa B (NF-kB) protein complex. This transcription factor
complex regulates expression of genes involved in biological
processes, such as proliferation, survival, and inflammation.
NF-kB signaling is constitutively active in CLL (Furman et al.,
2000), while high levels of the pro-survival gene BCL2, an estab-
lished NF-kB target, are a hallmark of the disease (Scarfo` and
Ghia, 2013).
Here, we provide direct evidence that BMF is transcrip-
tionally regulated by RELA, in keeping with the somewhat
counter-intuitive observation that levels of pro-apoptotic
BMF are high in CLL (Mackus et al., 2005). In the normal
response to cellular stress, BMF interacts with BCL2 at the
mitochondrial surface and neutralizes its anti-apoptotic prop-
erties (Puthalakath et al., 2001). In CLL, it is hypothesized
that, although cells maintain some ability to induce pro-
apoptotic BH3-only proteins like BMF in response to onco-2064 Cell Reports 16, 2061–2067, August 23, 2016genic stress, apoptosis ultimately fails due to overexpression
of pro-survival proteins.
Our data suggest that, in individuals carrying the rs539846 risk
allele, BMF transcript levels are reduced and thus the apoptotic
response may be attenuated further. Indeed, previous studies in
the myeloma cell line U266 have reported that siRNA-mediated
knockdown of BMF is associated with a decrease in apoptosis
following treatment with arsenic trioxide (Morales et al., 2008),
whereas mice lacking Bmf develop a B cell lymphadenopathy
caused by a resistance of B cells to apoptosis (Labi et al., 2008).
We did not observe an association between the SNP and
prognostic markers or patient survival in CLL. This is consistent
with differential expression of BMF being important in the early
phases of CLL rather than disease progression per se. We do,
however, acknowledge that our analysis had <50% power to
demonstrate a 10% difference in patient outcome, and to
robustly determine the relationship between BMF expression
and patient outcome requires much larger patient cohorts.
Finally, this study underlines the importance of BH3-only pro-
teins such as BMF in CLL development. Recently, a number of
BH3 mimetics have been developed as potential therapies for
lymphoid malignancies (Billard, 2013). These molecules are de-
signed to mimic endogenous BH3-only proteins and bind to
pro-survival members of the BCL2 family, facilitating the induc-
tion of apoptosis. One example, ABT-199 (Venetoclax), selec-
tively targets BCL2, and, in recent clinical trials involving
relapsed or refractory CLL, patients gave an overall response
rate of 79% (Roberts et al., 2016). Our findings thus further
demonstrate the utility of association studies to define clinically
relevant oncogenic pathways.
Figure 4. RELA Expression and the
rs539846 Genotype Are Correlated with
BMF Transcript Levels
(A) siRNA knockdown of RELA reduces transcript
levels of BMF. Data shown are mean ± SE for three
independent replicates relative to GAPDH refer-
ence mRNA, normalized to control siRNA. The
p values were determined with a two-tailed t test.
(B) The rs539846 CLL risk allele (A) was associated
with lower BMF mRNA levels in 462 patient sam-
ples. Boxplot indicates themedian (horizontal line),
first to third quartiles (box), and 1.5 times the in-
terquartile range (whiskers) of BMF expression.EXPERIMENTAL PROCEDURES
Ethics
Ethical approval for this studywas obtained from the UKMulti-Research Ethics
Committee (MREC 99/1/082).
Fine-Mapping of the 15q15.1 Locus
We made use of data from two published CLL GWASs: (1) UK-CLL-1 (Di Ber-
nardo et al., 2008), a scan of 517 cases using Illumina HumanCNV370-Duo
BeadChips, with Hap1.2M-Duo Custom array data on 2,698 individuals from
the Wellcome Trust Case Control Consortium 2 (WTCCC2) 1958 Birth cohort
serving as controls; and (2) UK-CLL-2 (Speedy et al., 2014), a scan of 1,403
cases using the Illumina Omni Express BeadChips, with Hap1.2M-Duo
Custom array data on 2,501 individuals from the UK Blood Service Control
Group serving as controls. Individuals with low call rate (<90%), extremely
high or low heterozygosity (p < 1.0 3 104), and those evaluated to be of
non-European ancestry (using HapMap version 2 populations as a reference)
were excluded.
GWAS data were imputed using 1000 Genomes Project phase 1 integrated
release 3 (Abecasis et al., 2012), and UK10K 2014 release (UK10K Consortium
et al., 2015) as a reference in conjunction with IMPUTE2 v2.1.1 software
(Howie et al., 2009). Genotypes were aligned to the positive strand in both
imputation and genotyping. Poorly imputed SNPs defined by an information
measure, Is < 0.80, were excluded. The association between each SNP and
CLL risk was assessed by Cochran-Armitage trend test. To look for indepen-
dent effects, conditional logistic regression analysis was performed. SNP
rs539846 was included as a covariate and association statistics for SNPs
within the interval chr15:40379030–40532514 were recalculated (region spans
all SNPs in LD r2 > 0.2 with rs539846). To validate imputed rs539846 geno-
types, we performed Sanger sequencing in 176 CLL GWAS cases. Primers
are listed in Table S5.
Epigenetic Annotation
To explore the epigenetic profile of the interval, we examined LCL chro-
matin state segmentation, DNase sequencing (DNase-seq), histone modifi-
cation, and transcription factor ChIP-seq data from the ENCODE project
(ENCODE Project Consortium, 2012; Ernst and Kellis, 2012). In addition,
ChIP-seq (H3K4me3, H3K4me1, and H3K27ac) and DNase-seq data
generated using standard protocols within the Blueprint Consortium,
from cells of a CLL patient with mutated IGHV (>90% tumor cell content),
also were examined (Puente et al., 2015). Detailed protocols are available
from the Blueprint Consortium (http://www.blueprint-epigenome.eu).
We also used HaploReg (Ward and Kellis, 2012) to examine whether
rs539846 or proxy SNPs (r2 > 0.2 in 1000 Genomes EUR reference panel)
annotate transcription factor-binding sites or enhancer elements. We
assessed sequence conservation using GERP (Cooper et al., 2005) and
PhastCons (Siepel et al., 2005). We searched for overlap with annotated su-
per-enhancer regions in lymphoid cell types from B cell (CD19+ and CD20+)
and T cell (CD4+ naive and memory; CD8+ naive and memory) lineages
(Hnisz et al., 2013).Hi-C and Definition of a Topological Domain at the 15q15.1 Locus
We made use of publicly available Hi-C data on GM12878 cells (Rao et al.,
2014), based on combined replicates digested using MboI, analyzed using
the balanced Knight-Ruiz normalization method (Knight and Ruiz, 2013) with
a uniform resolution of 5 kb. Contact domains were defined with the Arrow-
head algorithm (Rao et al., 2014).
Cell Culture
MEC1 (human CLL) cells were grown in Iscove’s modified Dulbecco’s medium
(Life Technologies) supplemented with 10% fetal calf serum.
4C-Seq
4C-seq libraries were prepared as described (van de Werken et al., 2012),
using ten million MEC1 cells cross-linked with 2% formaldehyde. Using
4C primer design software (http://mnlab.uchicago.edu/4Cpd/), we identified
a viewpoint adjacent to SNP rs539846. Primary and secondary restriction
enzymes were DpnII and HindIII (cut sites, chr15:40,397,659–40,397,662 bp
and chr15:40,396,692–40,396,697 bp, respectively). Primers are listed in
Table S5. Libraries were sequenced on an IlluminaMiSeq to obtain 150-bp sin-
gle-end reads.Readsweremapped to thehumangenomeusingBowtie (version
2.1.0) and filtered for PHRED score < 30. Implementing standard procedures,
unique 4C-seq reads were allocated to blind and non-blind fragments. Profiles
for the two classes of fragments were obtained at 100-bp resolution and an
averageprofile for a 5-kb runningwindowwascomputed. Fordata visualization,
we used Vispig (Scales et al., 2014) and incorporated processedChIP-seq data
from the ENCODE Project (ENCODE Project Consortium, 2012).
Plasmid Construction and Luciferase Assays
Allele-specific fragments of a 591-bp region spanning rs539846 were ampli-
fied from human genomic DNA using primers detailed in Table S5, cloned
into the PCR8/GW/TOPO vector, and then transferred into pGL3 luc2 pro-
moter vector using Gateway technology (Life Technologies). Reporter con-
structs were introduced into MEC1 cells by nucleofection, using program
X-01 on the Amaxa Nucleofector I (Amaxa Biosystems). Typically, 53 106 cells
were resuspended in 100 ml Cell Line Nucleofector Solution V and mixed with
3 mg reporter plasmid DNA and 60 ng internal control plasmid (pRL-SV40).
Transiently transfected cells were grown for 24 hr before assaying with the
Dual-Luciferase Reporter Assay System (Promega) and the Fluoroskan Ascent
FL plate reader (Labsystems). Relative luciferase activity was calculated as the
ratio of luminescence from the experimental reporter to that of the control re-
porter. Each transfection experiment was repeated three times and statistical
significance was calculated using the Student’s t test.
EMSA
Nuclear protein was extracted from MEC1 cells using NE-PER nuclear and
cytoplasmic extraction kits (Thermo Fisher Scientific). Infrared dye DY-682-
labeled (Eurofins Genomics) and unlabeled (Life Technologies) complemen-
tary oligonucleotides flanking rs539846 (50-GAGGGGACTTT[C/A]CCTCCCC
AAAC-30 and 50-GTTTGGGGAGG[G/T]AAAGTCCCCTC-30) were annealed
to generate double-stranded EMSA probes. Each 20 ml binding reactionCell Reports 16, 2061–2067, August 23, 2016 2065
contained 50 fmol labeled target DNA, 13 binding buffer (10 mM Tris, 50 mM
KCl, 1 mM DTT [pH 7.5], 1 mg poly [dI.dC, Sigma-Aldrich], 2.5 mM DTT, and
10 mg nuclear protein extract). The reaction mix was incubated in the dark
for 30 min at room temperature. Competition assays were performed by add-
ing 200-fold molar excess of unlabeled probes to the binding reaction. Super-
shift EMSAs were conducted by adding 2 mg RELA antibody (Santa Cruz
Biotechnology) to the binding reaction and incubating for 15 min prior to the
addition of labeled probe. Post-incubation, 2 ml 103 Orange loading dye (LI-
COR Biosciences) was added to the reaction mix, and the DNA-protein com-
plexes were resolved by electrophoresis on a 6% DNA retardation gel (Life
Technologies) in 0.53 Tris-borate-EDTA (TBE) at 4C. Gels were imaged using
the Odyssey Fc Infrared Imaging System (LI-COR Biosciences).
Gene Expression and Splicing Analysis
We used Spearman’s rank correlation to assess the relationship between BMF
and RELA transcript levels in the ICGC dataset (Puente et al., 2015). Expres-
sion quantitative trait locus analyses were performed for all genes in the
1-Mb region around rs539846, using Affymetrix Human Genome Array U219
data on 426 CLL patients (Puente et al., 2015). Four cases with 15q15.1
copy number losses were excluded. Genotypes were determined by imputa-
tion as described and were confirmed fromwhole-genome-sequencing (WGS)
data in 145 samples, with >99% concordance. The association between SNP
genotype and expression was evaluated by linear regression controlling for
false discovery using matrixEQTL (Shabalin, 2012) implemented in R (version
3.2.0). To assess the impact of rs539846 on splicing, we used RNA-seq data
from CLL tumors (Puente et al., 2015), counting individual k-mers supporting
each of the possible splicing events. Sample genotype for SNP rs539846
was determined from WGS data, and differences between k-mer counts for
rs539846-CC and -AA homozygotes were evaluated using a Student’s t test.
The accession numbers for the data utilized in this paper are European
Genome-phenome Archive EGAD00010000875 and EGAS00000000092.
siRNA Knockdown
siRNA targeting RELA and a control siRNA (Table S5) were obtained from
Eurofins Genomics. MEC1 cells were transfected with 100 nM siRNA using
nucleofection as described. Total RNA was extracted 24 hr post-transfection
using the RNeasy Plus Mini Kit (QIAGEN). The cDNA was produced using
SuperScript II Reverse Transcriptase (Life Technologies). Knockdown effi-
ciency was measured by qPCR and western blot using standard protocols.
RELA antibody was used with GAPDH antibody (FL-335; sc-25778, horse-
radish peroxidase [HRP]; Santa Cruz Biotechnology) as the loading control.
Transcript levels of RELA and BMF were quantified using SYBR Green PCR
mastermix (Life Technologies) and normalized to GAPDH. The experiment
was repeated three times. Primer sequences are detailed in Table S5.
Association between the rs539846 Genotype and Clinical Variables
Logistic regression was used to test the association between the rs539846
genotype and prognostic factors. Trisomy 12, 13q14 deletion, 6q21 deletion,
11q23 deletion, 17p13 deletion, CD38 expression, ZAP70 expression, CLLU1
expression,NOTCH1mutation, andSF3B1mutation statuseswere determined
in a subset of UK-CLL-1 patients who were participants in the LRF CLL4 Trial
(Catovsky et al., 2007), as previously described (Gonzalez et al., 2013; Oscier
et al., 2010, 2013). IGHVmutation statuswasdeterminedasperBIOMED-2pro-
tocols (van Dongen et al., 2003) in a subset of patients from UK-CLL-1, UK-
CLL-2, and the ICGCCLL project (Puente et al., 2015). In accordance with pub-
lished criteria (van Krieken et al., 2007), we classified sequences with germline
homology ofR98%as unmutated and thosewith homology <98%asmutated.
Survival analysis was performed using data from a subset of UK-CLL-1 and
ICGCCLL project cases. Analysis was carried out using the log-rank test (using
time from diagnosis to death or censoring at the end of follow-up).
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